|
Variable
|
Pre-RT CRP (mg/L)
|
Post-RT CRP (mg/L)
|
|---|
|
N
|
Mean
|
SD
|
MD
|
P
1
|
N
|
Mean
|
SD
|
MD
|
P
1
|
|---|
|
Study population
|
362
|
6.5
|
9.3
|
3.5
| |
338
|
6.1
|
8.9
|
3.5
|
0.6462
|
|
Race/ethnicity
|
|
NHW
|
58
|
6.1
|
12.4
|
2.8
|
0.879
|
53
|
5.2
|
12.1
|
2.2
|
0.541
|
|
AA
|
71
|
6.9
|
8.0
|
4.4
| |
66
|
7.0
|
6.7
|
5.5
| |
|
HW
|
233
|
6.4
|
8.8
|
3.5
| |
219
|
6.0
|
8.6
|
3.7
| |
|
Age (years)
|
|
< 50
|
94
|
6.2
|
10.7
|
3.1
|
0.797
|
86
|
5.6
|
10.1
|
2.8
|
0.571
|
|
≥ 50
|
268
|
6.5
|
8.8
|
3.7
| |
252
|
6.2
|
8.5
|
3.9
| |
|
BMI (kg/m2)
|
|
< 25
|
94
|
3.1
|
6.3
|
1.2
|
0.0001
|
87
|
3.1
|
8.4
|
1.4
|
0.0009
|
|
25–29.99
|
124
|
7.3
|
11.0
|
3.7
| |
117
|
6.5
|
9.5
|
3.8
| |
|
≥ 30
|
144
|
8.0
|
8.8
|
4.9
| |
134
|
7.7
|
8.4
|
5.3
| |
|
Smoking history
|
|
Never
|
238
|
5.8
|
8.6
|
3.4
|
0.066
|
225
|
5.4
|
7.8
|
3.4
|
0.046
|
|
Ever
|
124
|
7.7
|
10.3
|
3.7
| |
113
|
7.4
|
10.7
|
3.9
| |
|
Pre-RT pain score
|
|
< 4
|
286
|
5.9
|
8.8
|
3.3
|
0.014
|
266
|
5.6
|
8.4
|
3.4
|
0.054
|
|
≥ 4
|
59
|
9.3
|
11.8
|
4.9
| |
56
|
8.1
|
10.3
|
4.2
| |
|
Post-RT pain score
|
|
< 4
|
230
|
5.4
|
8.2
|
3.1
|
0.007
|
226
|
5.3
|
7.8
|
3.2
|
0.014
|
|
≥ 4
|
101
|
8.3
|
9.9
|
4.6
| |
99
|
7.9
|
11.0
|
4.8
| |
|
Tumor stage
|
|
0
|
73
|
6.1
|
8.2
|
3.6
|
0.916
|
65
|
6.3
|
8.3
|
3.4
|
0.872
|
|
IA-B
|
180
|
6.4
|
10.0
|
3.3
| |
165
|
6.3
|
10.8
|
3.4
| |
|
IIA-III
|
109
|
6.7
|
8.8
|
3.9
| |
108
|
5.7
|
5.7
|
4.2
| |
|
Breast volume (cc)
|
|
< 892.1 cc (median)
|
181
|
5.2
|
8.2
|
2.6
|
0.011
|
169
|
5.0
|
9.2
|
2.4
|
0.021
|
|
≥ 892.1 cc (median)
|
177
|
7.7
|
10.2
|
4.6
| |
165
|
7.2
|
8.6
|
5.0
| |
|
Hormone therapy
|
|
None/after RT
|
175
|
6.7
|
10.5
|
3.2
|
0.736
|
159
|
5.7
|
7.9
|
3.3
|
0.032
|
|
AI before
|
97
|
6.7
|
7.7
|
4.8
| |
95
|
7.2
|
10.0
|
4.6
| |
|
AI during
|
14
|
4.5
|
4.0
|
3.3
| |
14
|
5.1
|
5.3
|
3.8
| |
|
Tamoxifen before
|
64
|
5.5
|
8.8
|
2.8
| |
59
|
4.3
|
6.0
|
2.4
| |
|
Tamoxifen during
|
12
|
8.2
|
9.3
|
5.1
| |
11
|
12.8
|
21.0
|
5.1
| |
|
RT fractionation
|
|
Conventional
|
302
|
6.4
|
9.1
|
3.5
|
0.632
|
289
|
6.2
|
9.2
|
3.5
|
0.575
|
|
Hypo
|
60
|
7.0
|
10.2
|
3.5
| |
49
|
5.4
|
7.0
|
3.7
| |
- 1P values from ANOVA; significant findings are in italics
- 2Paired t test comparing pre- and post-RT CRP
- Abbreviations: NHW non-Hispanic whites, AA black or African American, HW Hispanic whites, BMI body mass index, AI aromatase inhibitor, SD standard deviation, MD median
